Journal
ONCOIMMUNOLOGY
Volume 6, Issue 12, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1386829
Keywords
antigen-presenting cell; autophagy; cytotoxic T lymphocyte; endoplasmic reticulum stress; damage-associated molecular pattern; dendritic cell; immune checkpoint blocker; type I interferon
Categories
Funding
- FWO Postdoctoral (Renewal) Fellowship from FWO-Vlaanderen, Belgium
- POR award funds from KU Leuven
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [642295, 675448]
- FWO [G060713 N, G076617 N]
- KU Leuven [C16/15/073]
- Ligue contre le Cancer (equipe labelisee)
- Agence National de la Recherche (ANR)
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- AXA Chair for Longevity Research
- Institut National du Cancer (INCa)
- Fondation Bettencourt-Schueller
- Fondation de France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- LabEx Immuno-Oncology
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Paris Alliance of Cancer Research Institutes (PACRI)
- WCMC (intramural funds)
- Sotio a.c. (Prague, Czech Republic)
Ask authors/readers for more resources
The expression immunogenic cell death (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as damage-associated molecular patterns. Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available